Share 'Summit Corporation plc : $1.5 million agreement secured with US DMD organisations'
SUMMIT SECURES $1.5M AGREEMENT WITH US DMD ORGANISATIONS
• Proceeds to fully fund new Phase I clinical trial of Summit's potential first-in-class DMD drug SMT C1100
• SMT C1100 has the potential to treat all DMD patients
Oxford, UK, 19 December 2011, Summit (AIM: SUMM), a UK drug discovery company, announces that it has entered into agreements collectively worth $1.5 million with several US-based…
You can share this discussion in two ways…
Share this link:
Send it with your computer's email program: Email this